The EMA has backed broader pediatric use of Agamree and Crysvita, lowering age thresholds for rare genetic diseases affecting muscle and bone development.

In collaboration with Johns Hopkins Medicine, Kennedy Krieger has started a program treating children with neurofibromatosis, a rare genetic tumor condition.

1. Bone cell biology: osteoclasts, osteoblasts, osteocytes / Katharine Jähn and Lynda F. Bonewald -- 2. Bone matrix and mineralization / Marc D. McKee and William G. Cole -- 3. Prenatal bone ...

Philadelphia, November 19, 2025 – Researchers at Children’s Hospital of Philadelphia (CHOP) revealed important genetic components that affect bone density in children and adolescents. This information ...

For most families, the journey toward a bone marrow transplant does not begin with a clear plan. It begins with uncertainty — a diagnosis that raises more questions than answers, repeated hospital ...

Large-scale analysis of patient cohorts reveals a novel mechanism driving osteosarcoma, an aggressive paediatric bone cancer. The researchers show that this mechanism occurs in approximately 50% of ...

The European Medicines Agency (EMA) has announced that its pilot program for the stepwise pediatric investigation plan (sPIP) has successfully supported timely pediatric development while maintaining ...

A pair of proteins could contribute to the development of healthy, strong bones by directing early cell movement and blood vessel generation. A pair of proteins, YAP and TAZ, has been identified as ...